{"id":2524,"date":"2026-08-10T00:00:00","date_gmt":"2026-08-10T04:00:00","guid":{"rendered":"https:\/\/www.insilens.com\/?p=2524"},"modified":"2026-08-13T02:52:39","modified_gmt":"2026-08-13T06:52:39","slug":"cd19-car-t-cells-persist-beyond-a-decade","status":"publish","type":"post","link":"https:\/\/www.insilens.com\/?p=2524","title":{"rendered":"CD19 CAR T Cells Persist Beyond a Decade"},"content":{"rendered":"

Company:<\/strong> University of Pennsylvania · Event Type:<\/strong> Technology and Modalities · Product\/Asset:<\/strong> CD19 CAR T · Subject:<\/strong> CAR T-Cell Therapy · Event Date:<\/strong> August 10, 2026<\/p>\n

\"CD19<\/p>\n

Summary<\/h4>\n

A peer-reviewed Nature Medicine study from the University of Pennsylvania characterized 4-1BB-costimulated CD19 CAR T cells up to 10.1 years after infusion in 38 patients with B-cell non-Hodgkin lymphoma. Beyond year five, the CAR transgene remained detectable in five of eight long-term responders, and three retained B-cell aplasia consistent with functional activity. The study is a high-value cell-therapy durability signal, but it does not prove that persistent cells caused remission. Deep multiomic conclusions are weighted toward an exceptional patient with abundant circulating CAR T cells at 9.3 years.<\/p>\n

What Happened<\/h4>\n

The investigators profiled patients treated in the early CTL019 program, the precursor to tisagenlecleucel. In one patient, CAR T cells represented 1.2% of circulating T cells 9.3 years after infusion. Long-lived cells were predominantly CD4-negative\/CD8-negative and effector-memory-like, with increased aerobic-metabolism and activation programs. T-cell receptor sequencing showed oligoclonality, including one clone accounting for 70% of CAR T cells at 9.3 years that was present below 0.1% on day 14. A dominant lentiviral integration within PACS1 was observed without evidence of a known driver of expansion.<\/p>\n

Deep Analysis<\/h4>\n

Interpretation 1 \u2014 a small number of early clones can acquire or retain a state that supports exceptional persistence and functional surveillance. Supporting evidence includes decade-scale transgene detection, persistent B-cell aplasia, oligoclonal expansion and a longitudinal shift toward double-negative effector-memory-like cells. Contradicting evidence is that detectable persistence was not universal among long-term responders and causality between the phenotype and clinical control cannot be established.<\/p>\n

Interpretation 2 \u2014 the double-negative state may be a consequence of chronic antigen exposure, selection or lineage remodeling rather than a design target. Supporting evidence includes progressive CD8-to-double-negative transition and metabolic activation. Contradicting evidence is that the most detailed observations come from one high-persistence patient, making it difficult to separate reproducible biology from an idiosyncratic clone or integration event.<\/p>\n

Evidence that would upgrade the platform implication includes prospective confirmation across products and diseases, mechanistic proof that the phenotype improves persistence without exhaustion, and engineering approaches that reproduce durable function without prolonged immunodeficiency. Evidence that would downgrade it includes failure to replicate the state or evidence that it reflects dysfunctional or risky clonal expansion. Detection of recurrent oncogenic integrations or secondary CAR-positive malignancy would falsify the benign-persistence interpretation.<\/p>\n

Signal Extraction<\/h4>\n
    \n
  • Verified facts:<\/strong> 38-patient cohort; CAR transgene detectable in five of eight responders beyond five years; three with ongoing B-cell aplasia; 1.2% circulating CAR T cells in one patient at 9.3 years; dominant double-negative phenotype; oligoclonal persistence; PACS1 integration without a known expansion driver.<\/li>\n
  • Independent corroboration:<\/strong> a linked long-term clinical analysis reported no lymphoma relapse beyond 5.4 years, but also substantial non-relapse mortality and second malignancies in the cohort.<\/li>\n
  • Missing facts:<\/strong> causal relationship between persistence and remission, representativeness across commercial manufacturing, exact late-infection burden by persistence state and whether double-negative cells are necessary or merely associated.<\/li>\n<\/ul>\n

    Insilens Take<\/h4>\n

    The study provides unusually deep evidence that a living drug can remain biologically active for a decade. Its translational value is the identification of testable cellular and clonal features, not a ready-made recipe for next-generation CAR T products. Persistent B-cell aplasia and infection burden are tradeoffs, and the dominant clone requires ongoing genomic surveillance. The next step is cross-product validation that separates beneficial persistence from chronic immune depletion and clonal risk.<\/p>\n

    Company and Product Background<\/h4>\n

    CD19 CAR T therapy uses autologous T cells engineered with a receptor that recognizes CD19 on malignant and normal B cells. The studied construct uses 4-1BB costimulation, which can favor memory and persistence compared with more acutely activating designs. Long-term persistence may sustain tumor surveillance but can also prolong B-cell aplasia and hypogammaglobulinemia, requiring immunoglobulin replacement and infection monitoring.<\/p>\n

    Importance and Confidence<\/h4>\n

    Signal Importance: 4\/5. Signal Direction: positive\/uncertain. Confidence in Facts: high. Confidence in Interpretation: medium. Red-team check: the report does not claim that persistence caused cure, that the double-negative phenotype is universally desirable or that one integration event is benign by default.<\/p>\n","protected":false},"excerpt":{"rendered":"

    A peer-reviewed Nature Medicine study from the University of Pennsylvania characterized 4-1BB-costimulated CD19 CAR T cells up to 10.1 years after infusion in 38 patients with B-cell non-Hodgkin lymphoma. Beyond year five, the CAR…<\/p>\n","protected":false},"author":5,"featured_media":2523,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[1,4],"tags":[329,328],"class_list":["post-2524","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-all-categories","category-technology-modalities","tag-car-t-cell-therapy","tag-university-of-pennsylvania"],"blocksy_meta":[],"_links":{"self":[{"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/posts\/2524","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/users\/5"}],"replies":[{"embeddable":true,"href":"https:\/\/www.insilens.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=2524"}],"version-history":[{"count":1,"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/posts\/2524\/revisions"}],"predecessor-version":[{"id":2525,"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/posts\/2524\/revisions\/2525"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/media\/2523"}],"wp:attachment":[{"href":"https:\/\/www.insilens.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=2524"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.insilens.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=2524"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.insilens.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=2524"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}